The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

About Us

Welcome to the National Advanced Therapy Medicinal Products (ATMP) Research School, where our mission is to advance the knowledge and expertise needed in the development of cell, gene, and tissue-based therapies in Sweden.

Advanced Therapy Medicinal Products (ATMPs) are revolutionary medicines based on cells, tissues, or genes. These therapies offer new possibilities for treating a wide range of severe diseases, from cancer to Parkinson's disease and diabetes. However, making these advanced treatments accessible to all remains a significant challenge.

The National ATMP Research School is a collaborative effort among five leading universities in Sweden: Lund University, Umeå University, Uppsala University, Karolinska Institutet, and the University of Gothenburg and is open to all Swedish higher education institutions. Together, we aim to advance the ATMP research field and create a sustainable educational platform that enables collaboration among academic, healthcare, and industry sectors, benefiting both professionals and society.

Our courses are designed to expand on standard doctoral offerings, providing new and relevant content jointly developed by our partner universities. These courses cover the entire spectrum of advanced therapy development, from initial research to clinical application.

By fostering connections between internationally recognized research environments and stakeholders in the Swedish ATMP ecosystem, we are working towards our vision of enabling patient access to ATMPs in Sweden.

Who is the research school for?

The National ATMP Research School primarily focuses on doctoral students in research fields related to advanced drug therapies (ATMP), who are considered future educators in relevant health and medical education programs.

Our Vision


Our vision is to enable patient access to ATMPs in Sweden by fostering the highest level of expertise among healthcare, academic, industry, regulatory, and legal professionals.

Our Mission


We are committed to establishing a sustainable ATMP education platform where Swedish academic, healthcare, and industry sectors collaborate to secure a leading global position in this field, ultimately benefiting society.

Our Funding


The National ATMP Research School has been awarded a grant of 46 million SEK from the Swedish Research Council.

This funding supports node managers' compensation, course development, students’ salary (each project application will receive 1,5 million SEK) remuneration for teachers, and conference facilities. The grant period spans from 2023 to 2027.

logos of the national ATMP research school partners